Revenue
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma, Inc. (BBIO)
Price$74.84Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | — | — |
| Gross profit | $481.1M | $218.0M | $6.9M | $74.2M | $66.6M | — | — | — | — |
| Gross margin | 95.82% | 98.25% | 73.71% | 95.58% | 95.53% | — | — | — | — |
| Research & development | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M | $30.6M |
| Operating expenses | $1.03B | $814.9M | $616.7M | $589.9M | $646.3M | $482.7M | $306.8M | $183.7M | $43.9M |
| Operating income | −$523.4M | −$593.0M | −$607.4M | −$512.2M | −$576.6M | −$474.5M | −$266.2M | −$183.7M | −$43.9M |
| Operating margin | −104.25% | −267.22% | −6,528.75% | −659.65% | −827.12% | −5,751.99% | −656.41% | — | — |
| EBITDA | −$518.0M | −$586.9M | −$600.9M | −$505.4M | −$570.8M | −$473.0M | −$265.4M | — | — |
| EBITDA margin | −103.17% | −264.49% | −6,458.95% | −650.93% | −818.73% | −5,734.34% | −654.29% | — | — |
| Net income | −$732.9M | −$543.3M | −$653.3M | −$484.7M | −$586.5M | −$505.5M | −$288.6M | −$169.5M | −$43.8M |
| Net profit margin | −145.98% | −244.86% | −7,021.94% | −624.17% | −841.20% | −6,127.87% | −711.50% | — | — |
| Basic EPSper basic share | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.90 | -$3.80 | -$2.48 | -$2.12 | -$1.00 |
| Diluted EPSper diluted share | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.90 | -$3.80 | -$2.48 | -$2.12 | -$1.00 |
Owners
Reported shareholders
7.23%of listed shares
Jupiter Topco LLC14.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 7.23%14.11M shares |
KRAVIS HENRY R / KKR Management LLP / KKR Genetic Disorder L.P. / KKR Genetic Disorder GP LLC / KKR Group Partnership L.P. / ROBERTS GEORGE R / KKR & Co. Inc. / KKR Group Holdings Corp. / KKR Group Co. Inc. | ≈6.79%13.26M shares |
Kohlberg Kravis Roberts & Co. L.P. | 6.79%13.26M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 5.50%10.74M shares |
BlackRock, Inc. | 5.27%10.29M shares |
VIKING GLOBAL INVESTORS LP | 5.09%9.95M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.04%7.9M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.92%7.66M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.72%5.31M shares |
Kumar Neil | ≈2.60%5.08M shares |
TWO SIGMA INVESTMENTS, LP | 2.42%4.72M shares |
Aisling Capital Management LP | 2.35%4.59M shares |
STATE STREET CORP | 2.27%4.44M shares |
CITADEL ADVISORS LLC | 1.93%3.76M shares |
Invesco Ltd. | 1.90%3.7M shares |
D. E. Shaw & Co., Inc. | 1.86%3.63M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.75%3.42M shares |
JANE STREET GROUP, LLC | 1.50%2.93M shares |
JPMORGAN CHASE & CO | 1.23%2.4M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.15%2.25M shares |
Percentages use 195.28M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 37.2K | $70.00 | $2.60M | 8.4K |
| Jun 23, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 2.2K | $68.57 | $150.6K | 8.4K |
| Jun 23, 2026Form 4 · 10b5-1 | Valantine HannahDirector | SellCommon Stock | 2.2K | $68.57 | $150.6K | 9.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Valantine HannahDirector | SellCommon Stock | 2.8K | $68.00 | $190.9K | 11.5K |
| Jun 15, 2026Form 4 · 10b5-1 | Cook Jennifer E.Director | SellCommon Stock | 1.5K | $67.14 | $100.9K | 6.6K |